(NASDAQ: GLSI) Greenwich Lifesciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 81.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.86%.
Greenwich Lifesciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast GLSI's revenue for 2027 to be $119,264,749, with the lowest GLSI revenue forecast at $119,264,749, and the highest GLSI revenue forecast at $119,264,749. On average, 1 Wall Street analysts forecast GLSI's revenue for 2028 to be $1,908,235,980, with the lowest GLSI revenue forecast at $1,908,235,980, and the highest GLSI revenue forecast at $1,908,235,980.
In 2029, GLSI is forecast to generate $4,233,898,581 in revenue, with the lowest revenue forecast at $4,233,898,581 and the highest revenue forecast at $4,233,898,581.